Cisplatin/paclitaxel or carboplatin/paclitaxel (with or without bevacizumab) is the preferred first-line treatment for PD-L1-positive (Combined Positive Score (CPS) ≥1) recurrent or metastatic cervical cancer, as supported by the Keynote-826 trial. Here, CD274 is linked to cervical carcinoma.